WHO global malaria strategy ‘off track by a wide margin’
HQ Team November 30, 2023: The Covid-19 pandemic significantly disrupted malaria services, leading to a surge in both incidence and mortality rates, exacerbating.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team November 30, 2023: The Covid-19 pandemic significantly disrupted malaria services, leading to a surge in both incidence and mortality rates, exacerbating.
HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.
HQ Team November 30, 2023: The COP28 has reached an agreement to operationalise a fund, known as ‘loss and damage’ to aid developing.
By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023.
HQ Team November 29, 2023: The first human case of a new swine flu variant in the UK has been detected by the.
HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.
HQ Team November 28, 2023: The USFDA has officially pulled out of its membership of the Global Harmonization Working Party (GHWP), an organization.
HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.